Skip to content

Activation of the Contact System and the Immune System in Patients With Chronic Kidney Disease.

Activation of the Contact System and the Immune System in Patients With Chronic Kidney

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05266092
Acronym
AKIM-CKD
Enrollment
400
Registered
2022-03-04
Start date
2022-04-25
Completion date
2032-04-30
Last updated
2022-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease Requiring Chronic Dialysis

Keywords

Contact system, Infection, Innate immune system, Coagulation, Chronic kidney disease, Hemodialysis, End-stage renal disease

Brief summary

Patients with end-stage renal disease undergoing hemodialysis (HD) are burdened with extremely high mortality rates (15% per year) and during the early stage (≤120days) the mortality rate is even higher (27% per year). Cardiovascular complications and bloodstream infections (BSIs) account for the vast majority of deaths in HD patients. In Denmark, BSIs occur in 14% of HD patients per year and is most frequently caused by Staphylococcus aureus (44%). The most frequent infectious complication is endocarditis that has fatal outcomes in ≈50% of the cases. Overall, 10% of HD patients die within 30 days after a positive blood culture for S. aureus. This project aims to answer key questions regarding HD patients' decreased ability to fight S. aureus BSIs and in particular the potential exacerbating effect of HD. We hypothesize that HD patients' blood is significantly compromised by the process of HD, to an extend that lowers immunoactivity against S. aureus. Moreover, we hypothesize, that contact activation promotes the coagulability of blood thus promoting biofilm formation by S. aureus which increases the overall risk of BSI. We will test these hypotheses by collecting blood and analyzing the inflammation and coagulation status in plasma samples from participants before and after HD. We will compare the level of the inflammatory markers in plasma from participants undergoing HD (n=180) to the level in plasma samples from three control groups: healthy volunteers (n=120), participants with renal disease not in dialysis (n=60) and participants undergoing peritoneal dialysis (n=40).

Interventions

OTHERObservational study

Observational study

Sponsors

University of Southern Denmark
CollaboratorOTHER
Odense University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Participants with chronic kidney disease undergoing hemodialysis Inclusion criteria * Age \>18 years * Chronic kidney disease * Hemodialysis

Exclusion criteria

\- Acute kidney disease Participants with chronic kidney disease, not in dialysis Inclusion criteria * Age \>18 years * Chronic kidney disease (eGFR from \<15 to 44)

Design outcomes

Primary

MeasureTime frameDescription
Plasma level of cHKAt enrollmentcHK is the final activation product of the contact activation system

Countries

Denmark

Contacts

Primary ContactKatrine Pilely, PhD
kapi@sdu.dk0045 20963328

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026